4 completed, 4 recruiting, 2 active not recruiting, 2 terminated. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 4, Recruiting 4, Active not recruiting 2, Terminated 2, Unknown 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Breast Carcinoma: new trials by email Literature Review of Breast Carcinoma trials Research Report on Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial Laser Therapy, Sham Intervention, Questionnaire Administration - Vaginal Atrophy, Breast Carcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 250 | 2026-04-21 | 2026-10-19 |
| Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer Regional Nodal Irradiation - Breast Carcinoma | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3142 | 2024-10-10 | 2025-01-03 |
| ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients Endocrine therapy, Endocrine therapy combined with the local treatment of FES-negative lesions, Chemotherapy - Breast Carcinoma | Phase 3 | Recruiting | Institut Curie | 300 | 2024-05-27 | 2026-04-17 |
| A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer Immediate Lymphatic Reconstruction, Volumetric arm measurements, Lymphatic massage - Lymphedema, Lymphedema Arm | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 285 | 2023-11-16 | 2026-11-10 |
| Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy eftilagimod alpha, Paclitaxel, placebo - Breast Carcinoma | Phase 2 / Phase 3 | Terminated | Immutep S.A.S. | 72 | 2023-05-22 | 2026-07-30 |
| Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation Denosumab, Placebo, Quality-of-Life Assessment - BRCA1 Mutation, Breast Cancer | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 300 | 2023-02-14 | 2026-10-05 |
| Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy Best Practice, Wound Dressing Material, Quality-of-Life Assessment - Breast Carcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 216 | 2022-07-26 | 2026-09-23 |
| Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel Cimetidine, Dexamethasone, Diphenhydramine - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 / Phase 3 | Completed | Ohio State University Comprehensive Cancer Center | 130 | 2021-10-07 | 2025-08-20 |
| Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer skin-oriented spa care, Pentoxifylline, Tocopherol acetate - Breast Carcinoma, Fibrosis | Phase 3 | Unknown | Institut de Cancérologie de Lorraine | 142 | 2018-12-01 | 2018-08-08 |
| Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride - Breast Carcinoma | Phase 3 | Completed | University of Rochester NCORP Research Base | 1363 | 2018-04-19 | 2025-09-25 |
| Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Indocyanine green, Technetium99, Optonuclear probe - Breast Carcinoma, Head and Neck Cancer | Phase 3 | Completed | Institut de Cancérologie de Lorraine | 744 | 2017-11-29 | 2026-09-01 |
| Oxybutynin Chloride in Managing Hot Flashes Oxybutynin Chloride, Placebo, Quality-of-Life Assessment - Breast Carcinoma, Ductal Breast Carcinoma In Situ | Phase 3 | Completed | Academic and Community Cancer Research United | 150 | 2016-12-09 | 2020-01-18 |
| Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Bevacizumab, Carboplatin, Paclitaxel - Breast Carcinoma, Recurrent Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 96 | 2007-11-01 | 2026-06-23 |
Breast Neoplasms (13) · Breast Carcinoma In Situ (2) · Neoplasms (2) · Anus Neoplasms (1) · Breast Diseases (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Squamous Cell (1) · Endometrial Neoplasms (1) · Fibrosis (1) · Head and Neck Neoplasms (1) · Hot Flashes (1) · Lymphedema (1) · Melanoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
Neoplasms by Site (13) · Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Breast Diseases (12) · Neoplasms (11) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Pathological Conditions, Signs and Symptoms (3) · Carcinoma in Situ (2) · Pathologic Processes (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Anus Diseases (1) · Colorectal Neoplasms (1)
Paclitaxel (3) · Calcium Dobesilate (2) · Dexamethasone (2) · auricularum (2) · dexamethasone 21-phosphate (2) · dexamethasone acetate (2) · Bandages (1) · Bevacizumab (1) · Carboplatin (1) · Cimetidine (1) · Denosumab (1) · Diphenhydramine (1) · Drug Therapy (1) · Famotidine (1) · Indocyanine Green (1)
Alliance for Clinical Trials in Oncology (3) · Institut de Cancérologie de Lorraine (2) · Academic and Community Cancer Research United (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Immutep S.A.S. (1) · Institut Curie (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · University of Rochester NCORP Research Base (1)
United States (9) · France (3) · Belgium (1) · China (1) · Georgia (1) · Moldova (1) · Spain (1)
Charles Loprinzi (1) · Ingrid Mayer (1) · Judy E. Garber, MD, MPH (1) · Kimberly Corbin, MD (1) · Luke Peppone (1) · Maryam Lustberg, MD, MPH (1) · Michael J Berger, Pharm.D. (1) · Michelle Coriddi, MD (1)
UG1CA189823 (3), 2016 (1), 2017 (1), 2023 (1), P30CA015083 (1), R01CA200579 (1), U10CA023318 (1), U10CA180794 (1), UG1CA189961 (1)